Evidence map›Paper›PMID 25811857›Full record

ArticlePloS one2015

Pharmacokinetics and Metabolism of 4R-Cembranoid.

Wanda Vélez-Carrasco, Carol E Green, Paul Catz, Anna Furimsky, Kathleen O'Loughlin, Vesna A Eterović, P A Ferchmin

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Investigating the spatiotemporal expression ofFrontiers in plant science · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wanda Vélez-CarrascoDepartment of Biochemistry, Universidad Central del Caribe, Bayamon, Puerto Rico, United States of America.
Carol E GreenSRI International Biosciences Division, Menlo Park, California, United States of America.
Paul CatzSRI International Biosciences Division, Menlo Park, California, United States of America.
Anna FurimskySRI International Biosciences Division, Menlo Park, California, United States of America.
Kathleen O'LoughlinSRI International Biosciences Division, Menlo Park, California, United States of America.
Vesna A EterovićDepartment of Biochemistry, Universidad Central del Caribe, Bayamon, Puerto Rico, United States of America.
P A FerchminDepartment of Biochemistry, Universidad Central del Caribe, Bayamon, Puerto Rico, United States of America.

Funding

Regulation of synaptic vesicle mobilization,priming and recycling by complexinU54NS083924 · NINDS · UNIVERSIDAD CENTRAL DEL CARIBE · PI BYKHOVSKAIA, MARIA · 2013 to 2015
$4.3M
PROTECTION AGAINST ORGANOPHOSPHATE NEUROTOXINS BY TOBACCO CEMBRANOIDSU01NS063555 · NINDS · UNIVERSIDAD CENTRAL DEL CARIBE · PI FERCHMIN, P. A. · 2008 to 2010
$2.0M
NINDS NIH HHS 1U54NS083924-01NINDS NIH HHS NS063555NINDS NIH HHS U01 NS063555NINDS NIH HHS U54 NS083924PHS HHS HHSN271200623691C
6 · The paper itself

Abstract

4R-cembranoid (4R) is a natural cyclic diterpenoid found in tobacco leaves that displays neuroprotective activity. 4R protects against NMDA, paraoxon (POX), and diisopropylfluorophosphate (DFP) damage in rat hippocampal slices and against DFP in rats in vivo. The purpose of this study was to examine the metabolism and pharmacokinetics of 4R as part of its preclinical development as a neuroprotective drug. 10 µM 4R was found to be very stable in plasma for up to 1 hr incubation. 4R metabolism in human microsomes was faster than in the rat. Ten metabolites of 4R were detected in the microsomal samples; 6 dihydroxy and 4 monohydroxy forms of 4R. Male rats received a single dose of 4R at 6 mg/kg i.v., i.m., or s.c. The i.v. group had the highest plasma concentration of 1017 ng/mL. The t1/2 was 36 min and reached the brain within 10 min. The brain peak concentration was 6516 ng/g. The peak plasma concentration in the i.m. group was 163 ng/mL compared to 138 ng/mL in the s.c. group. The t1/2 of 4R after i.m. and s.c. administration was approximately 1.5 hr. The brain peak concentration was 329 ng/g in the i.m. group and 323 ng/g for the s.c. group. The brain to plasma ratio in the i.v. group was 6.4, reached 10 min after dose, whereas in the i.m. and s.c. groups was 2.49 and 2.48, respectively, at 90 min after dose. Our data show that 4R crosses the BBB and concentrates in the brain where it exerts its neuroprotective effect.

Indexed as

AnimalsDiterpenesFemaleHumansMaleMetabolomeMicrosomes, LiverRats, Sprague-Dawleycembra-2,7,11-triene-4,6-diolDiterpenes

Identifiers

PMID25811857
PMCPMC4374761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.